Ferraro Daniela A, Burger Irene A
Department of Nuclear Medicine, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland.
Top Magn Reson Imaging. 2020 Feb;29(1):59-66. doi: 10.1097/RMR.0000000000000229.
Positron-emission tomography (PET) with prostate-specific membrane antigen (PSMA) has been increasingly used to image prostate cancer in the last decade. In the staging setting several studies have already been published suggesting PSMA PET can be a valuable tool. They, however, did not translate into recommendations by guidelines. Both PSMA PET/computed tomography (CT) and PET/magnetic resonance imaging have been investigated in the staging setting, showing higher detection rate of prostate cancer lesions over the conventional imaging work-up and some studies already showed an impact on disease management. The aim of this review is to provide an overview of the existing published data regarding PSMA PET for staging prostate cancer, with emphasis on PET/magnetic resonance imaging. Despite the fact that PSMA is a relatively new tool and not officially recommended for staging yet, there are >50 original studies in the literature assessing PSMA PET performance in the staging setting of prostate cancer, and some meta-analyses.
在过去十年中，正电子发射断层扫描（PET）联合前列腺特异性膜抗原（PSMA）越来越多地用于前列腺癌成像。在分期方面，已经发表了几项研究，表明PSMA PET可能是一种有价值的工具。然而，它们并未转化为指南中的推荐意见。PSMA PET/计算机断层扫描（CT）和PET/磁共振成像均已在分期方面进行了研究，结果显示与传统成像检查相比，前列腺癌病灶的检出率更高，并且一些研究已经表明其对疾病管理有影响。本综述的目的是概述关于PSMA PET用于前列腺癌分期的现有已发表数据，重点是PET/磁共振成像。尽管PSMA是一种相对较新的工具，尚未被正式推荐用于分期，但文献中有>50项原始研究评估了PSMA PET在前列腺癌分期中的性能，还有一些荟萃分析。
